 Lucinda Kohn
Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatology | 7 | 2025 | 127 | 4.500 |
Why?
| | Acne Vulgaris | 2 | 2024 | 29 | 1.630 |
Why?
| | Dermatologic Agents | 2 | 2024 | 70 | 1.340 |
Why?
| | Skin Neoplasms | 6 | 2022 | 855 | 1.250 |
Why?
| | Telemedicine | 3 | 2023 | 862 | 1.250 |
Why?
| | Hemangioma | 3 | 2021 | 48 | 1.130 |
Why?
| | Isotretinoin | 2 | 2024 | 26 | 1.090 |
Why?
| | Indians, North American | 2 | 2024 | 643 | 1.080 |
Why?
| | Skin Diseases | 3 | 2024 | 149 | 1.070 |
Why?
| | Private Practice | 1 | 2024 | 25 | 0.880 |
Why?
| | Peer Review, Research | 1 | 2023 | 43 | 0.790 |
Why?
| | Myofibroma | 1 | 2022 | 4 | 0.760 |
Why?
| | Myofibromatosis | 1 | 2022 | 10 | 0.760 |
Why?
| | Incontinentia Pigmenti | 1 | 2022 | 3 | 0.760 |
Why?
| | Ectodermal Dysplasia | 1 | 2022 | 19 | 0.750 |
Why?
| | Hemangioma, Capillary | 1 | 2021 | 13 | 0.730 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2022 | 69 | 0.720 |
Why?
| | Soft Tissue Neoplasms | 1 | 2022 | 115 | 0.690 |
Why?
| | Alaska Natives | 1 | 2023 | 150 | 0.660 |
Why?
| | Melanoma | 2 | 2024 | 760 | 0.640 |
Why?
| | Internet | 1 | 2024 | 655 | 0.630 |
Why?
| | Glucocorticoids | 2 | 2024 | 594 | 0.530 |
Why?
| | Biomedical Research | 1 | 2023 | 692 | 0.510 |
Why?
| | Parents | 1 | 2025 | 1347 | 0.510 |
Why?
| | Triamcinolone Acetonide | 1 | 2016 | 28 | 0.510 |
Why?
| | Health Services Accessibility | 1 | 2023 | 986 | 0.460 |
Why?
| | Hydrocortisone | 1 | 2016 | 322 | 0.420 |
Why?
| | Dermatitis, Atopic | 1 | 2016 | 329 | 0.390 |
Why?
| | Propranolol | 2 | 2021 | 50 | 0.390 |
Why?
| | Quality of Life | 1 | 2024 | 2892 | 0.370 |
Why?
| | Child | 8 | 2025 | 21935 | 0.360 |
Why?
| | Humans | 24 | 2025 | 137585 | 0.330 |
Why?
| | Administration, Cutaneous | 2 | 2021 | 129 | 0.300 |
Why?
| | Adolescent | 5 | 2025 | 21513 | 0.270 |
Why?
| | Sirolimus | 3 | 2013 | 276 | 0.270 |
Why?
| | Qualitative Research | 2 | 2025 | 1386 | 0.260 |
Why?
| | Infant | 6 | 2022 | 9465 | 0.250 |
Why?
| | Pemphigoid, Bullous | 1 | 2014 | 9 | 0.220 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 683 | 0.220 |
Why?
| | Dermatitis, Exfoliative | 1 | 2013 | 4 | 0.220 |
Why?
| | Cicatrix | 1 | 2024 | 64 | 0.220 |
Why?
| | Pigmentation Disorders | 1 | 2013 | 9 | 0.210 |
Why?
| | Prednisone | 1 | 2024 | 240 | 0.210 |
Why?
| | Anilides | 1 | 2013 | 73 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2013 | 67 | 0.200 |
Why?
| | Communicable Disease Control | 1 | 2023 | 82 | 0.200 |
Why?
| | Child, Preschool | 3 | 2025 | 11074 | 0.190 |
Why?
| | Carcinoma, Basal Cell | 1 | 2013 | 75 | 0.190 |
Why?
| | I-kappa B Kinase | 1 | 2022 | 55 | 0.180 |
Why?
| | Drug Monitoring | 1 | 2013 | 218 | 0.180 |
Why?
| | Paresthesia | 1 | 2021 | 15 | 0.180 |
Why?
| | Drug Therapy, Combination | 1 | 2024 | 1066 | 0.180 |
Why?
| | Sarcoma, Kaposi | 2 | 2017 | 81 | 0.180 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 323 | 0.180 |
Why?
| | Social Class | 1 | 2023 | 282 | 0.170 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 224 | 0.170 |
Why?
| | Health Services Needs and Demand | 1 | 2023 | 273 | 0.170 |
Why?
| | Male | 9 | 2025 | 67762 | 0.170 |
Why?
| | Educational Status | 1 | 2023 | 470 | 0.170 |
Why?
| | Physician-Patient Relations | 1 | 2025 | 548 | 0.170 |
Why?
| | Female | 9 | 2025 | 73304 | 0.170 |
Why?
| | Language | 1 | 2023 | 292 | 0.170 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 411 | 0.160 |
Why?
| | Self Report | 1 | 2024 | 827 | 0.160 |
Why?
| | Patient Education as Topic | 1 | 2014 | 766 | 0.160 |
Why?
| | Pyridines | 1 | 2013 | 506 | 0.160 |
Why?
| | Bone and Bones | 1 | 2022 | 317 | 0.150 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 261 | 0.150 |
Why?
| | Adiponectin | 1 | 2011 | 244 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2025 | 654 | 0.150 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2011 | 446 | 0.140 |
Why?
| | Patient Satisfaction | 1 | 2022 | 660 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 804 | 0.140 |
Why?
| | Foot Diseases | 1 | 2017 | 15 | 0.140 |
Why?
| | Pediatrics | 1 | 2025 | 1101 | 0.130 |
Why?
| | Ointments | 1 | 2016 | 25 | 0.130 |
Why?
| | Retrospective Studies | 3 | 2023 | 15657 | 0.130 |
Why?
| | Adult | 3 | 2025 | 37929 | 0.120 |
Why?
| | Single-Blind Method | 1 | 2016 | 282 | 0.120 |
Why?
| | Young Adult | 2 | 2023 | 13209 | 0.120 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 2129 | 0.110 |
Why?
| | Proteins | 1 | 2011 | 1009 | 0.110 |
Why?
| | Pandemics | 1 | 2023 | 1639 | 0.110 |
Why?
| | Middle Aged | 5 | 2023 | 33479 | 0.110 |
Why?
| | Immunocompromised Host | 1 | 2016 | 202 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 786 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1809 | 0.110 |
Why?
| | Mutation | 2 | 2022 | 3958 | 0.110 |
Why?
| | Colorado | 1 | 2024 | 4565 | 0.110 |
Why?
| | Hospitalization | 1 | 2013 | 2199 | 0.100 |
Why?
| | Imatinib Mesylate | 2 | 2013 | 79 | 0.100 |
Why?
| | Water | 1 | 2016 | 460 | 0.100 |
Why?
| | Transcription Factors | 1 | 2011 | 1719 | 0.100 |
Why?
| | Organ Transplantation | 1 | 2016 | 250 | 0.100 |
Why?
| | Medication Adherence | 1 | 2016 | 467 | 0.100 |
Why?
| | Benzamides | 2 | 2013 | 216 | 0.100 |
Why?
| | Pain | 1 | 2017 | 756 | 0.090 |
Why?
| | Double-Blind Method | 1 | 2016 | 1993 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5778 | 0.090 |
Why?
| | Piperazines | 2 | 2013 | 350 | 0.090 |
Why?
| | Pyrimidines | 2 | 2013 | 470 | 0.080 |
Why?
| | Prospective Studies | 1 | 2022 | 7604 | 0.080 |
Why?
| | Aged | 3 | 2023 | 23961 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2828 | 0.070 |
Why?
| | Macrophages | 1 | 2016 | 1547 | 0.070 |
Why?
| | United States | 1 | 2024 | 14841 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2021 | 10811 | 0.060 |
Why?
| | Pruritus | 1 | 2014 | 63 | 0.050 |
Why?
| | Watchful Waiting | 1 | 2014 | 81 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2014 | 329 | 0.050 |
Why?
| | Mesylates | 1 | 2013 | 7 | 0.050 |
Why?
| | Dermatofibrosarcoma | 1 | 2013 | 9 | 0.050 |
Why?
| | Ipilimumab | 1 | 2013 | 33 | 0.050 |
Why?
| | Bradycardia | 1 | 2013 | 55 | 0.050 |
Why?
| | Cetuximab | 1 | 2013 | 98 | 0.050 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 127 | 0.050 |
Why?
| | Hypotension | 1 | 2013 | 122 | 0.050 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2011 | 35 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2011 | 125 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 191 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2014 | 893 | 0.040 |
Why?
| | Indoles | 1 | 2013 | 412 | 0.040 |
Why?
| | Multiprotein Complexes | 1 | 2011 | 163 | 0.040 |
Why?
| | Skin | 1 | 2014 | 752 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2011 | 197 | 0.040 |
Why?
| | Sulfonamides | 1 | 2013 | 513 | 0.040 |
Why?
| | Heart Rate | 1 | 2013 | 822 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 437 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2013 | 445 | 0.040 |
Why?
| | Immunotherapy | 1 | 2013 | 641 | 0.040 |
Why?
| | Hemodynamics | 1 | 2013 | 1113 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2011 | 412 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2011 | 1353 | 0.030 |
Why?
| | Lymphedema | 1 | 2017 | 24 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 617 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 916 | 0.030 |
Why?
| | Caregivers | 1 | 2014 | 877 | 0.030 |
Why?
| | Blood Pressure | 1 | 2013 | 1786 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1430 | 0.030 |
Why?
| | Arginase | 1 | 2016 | 32 | 0.030 |
Why?
| | Carcinoma in Situ | 1 | 2016 | 49 | 0.030 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 61 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2011 | 785 | 0.030 |
Why?
| | CD40 Antigens | 1 | 2016 | 89 | 0.030 |
Why?
| | Cell Count | 1 | 2016 | 324 | 0.030 |
Why?
| | Cell Polarity | 1 | 2016 | 141 | 0.030 |
Why?
| | Macrophage Activation | 1 | 2016 | 201 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2011 | 4193 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2011 | 1991 | 0.030 |
Why?
| | Blood Glucose | 1 | 2013 | 2186 | 0.030 |
Why?
| | Antigens, CD | 1 | 2016 | 521 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2016 | 7635 | 0.010 |
Why?
|
|
Kohn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|